Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study

被引：0
|
作者：
Montalban, X. [1 ]
Hemmer, B. [2 ,3 ]
Rammohan, K. [4 ]
Giovannoni, G. [5 ]
de Seze, J. [6 ]
Bar-Or, A. [7 ]
Arnold, D. L. [7 ,8 ]
Sauter, A. [9 ]
Kakarieka, A. [9 ]
Masterman, D. [10 ]
Chin, P. [10 ]
Garren, H. [9 ]
Wolinsky, J. [11 ]
机构：
[1] Hosp Vall dHebron Univ, Barcelona, Spain
[2] Tech Univ Munich, D-80290 Munich, Germany
[3] Munich Cluster Syst Neurol SyNergy, Munich, Germany
[4] Univ Miami, Miami, FL USA
[5] Queen Mary Univ London, London, England
[6] Univ Hosp Strasbourg, Strasbourg, France
[7] McGill Univ, Montreal, PQ, Canada
[8] NeuroRx Res, Montreal, PQ, Canada
[9] F Hoffmann La Roche Ltd, Basel, Switzerland
[10] Genentech Inc, San Francisco, CA 94080 USA
[11] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
228
引用
收藏
页码：781 / 782
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled ORATORIO Study
    Montalban, Xavier
    Hemmer, Bernhard
    Rammohan, Kottil
    Giovannoni, Gavin
    De Seze, Jerome
    Bar-Or, Amit
    Arnold, Douglas
    Sauter, Annette
    Masterman, Donna
    Fontoura, Paulo
    Garren, Hideki
    Chin, Peter
    Wolinsky, Jerry
    [J]. NEUROLOGY, 2016, 86
  • [2] Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis
    de Seze, J.
    Montalban, X.
    McDougall, F.
    Sauter, A.
    Deol-Bhullar, G.
    Wolinsky, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 677 - 678
  • [3] Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis
    de Seze, Jerome
    Montalban, Xavier
    McDougall, Fiona
    Julian, Laura
    Sauter, Annette
    Deol-Bhullar, Gurpreet
    Wolinsky, Jerry
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (01) : 84 - 84
  • [4] Infusion-related reactions in the Phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis (PPMS)
    Montalban, X.
    Arnold, D.
    Bar-or, A.
    de Seze, J.
    Giovannoni, G.
    Hemmer, B.
    Rammohan, K.
    Mairon, N.
    Chin, P.
    Fontoura, P.
    Garren, H.
    Masterman, D.
    Sauter, A.
    Wolinsky, J.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 410 - 410
  • [5] Efficacy and safety of siponimod in secondary progressive multiple sclerosis - Results of the placebo controlled, double-blind, Phase III EXPAND study.
    Kappos, L.
    Bar-Or, A.
    Cree, B.
    Fox, R.
    Giovannoni, G.
    Gold, R.
    Vermersch, P.
    Arnould, S.
    Sidorenko, T.
    Wolf, C.
    Wallstroem, E.
    Dahlke, F.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 828 - 829
  • [6] Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, multicenter trial
    Hawker, Kathleen S.
    O'Connor, Paul
    Freedman, Mark S.
    Calabresi, Peter A.
    Antel, Jack P.
    Simon, Jack
    Hauser, Stephen L.
    Waubant, Emmanuelle
    Vollmer, Timothy
    Panitch, Hillel
    Zhang, Jiameng
    Chin, Peter
    Smith, Craig
    [J]. MULTIPLE SCLEROSIS, 2008, 14 : S299 - S299
  • [7] Efficacy and Safety of Rituximab in Patients with Primary Progressive Multiple Sclerosis (PPMS): Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
    Hawker, Kathleen
    O'Connor, Paul
    Freedman, Mark
    Calabresi, Peter
    Antel, Jack
    Simon, Jack
    Hauser, Stephen
    Waubant, Emmanuelle
    Vollmer, Timothy
    Paniteh, Hillel
    Zhang Jia-meng
    Chin, Peter
    Smith, Craig H.
    [J]. NEUROLOGY, 2009, 72 (11) : A254 - A254
  • [8] Efficacy and safety of oxycodone DETERx: results of a randomized, double-blind, placebo-controlled phase III study
    Kopecky, E.
    O'Connor, M.
    Varanasi, R.
    Saim, S.
    Fleming, A.
    [J]. JOURNAL OF PAIN, 2015, 16 (04): : S87 - S87
  • [9] Phase III Study of Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis: ORATORIO Study Design
    Montalban, Xavier
    Wolinsky, Jerry
    Yin, Ming
    Leppert, David
    Glanzman, Robert
    Chin, Peter
    [J]. NEUROLOGY, 2011, 76 (09) : A319 - A320
  • [10] Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
    Hawker, Kathleen
    O'Connor, Paul
    Freedman, Mark S.
    Calabresi, Peter A.
    Antel, Jack
    Simon, Jack
    Hauser, Stephen
    Waubant, Emmanuelle
    Vollmer, Timothy
    Panitch, Hillel
    Zhang, Jiameng
    Chin, Peter
    Smith, Craig H.
    [J]. ANNALS OF NEUROLOGY, 2009, 66 (04) : 460 - 471
12345